Mesothelin (MESO) was highly expressed in a variety of solid tumors, such as pleural mesothelioma, ovarian cancer, and non-small cell lung cancer (NSCLC) and was low expressed in small number of normal tissue cells, such as pleura, peritoneum, and pericardium mesothelin cells, thus posing a good target for CAR-T cell therapy (5). The gene discussed is MSLN; the disease is non-small cell lung carcinoma.